Cell: Kinase is a potential target for new coronavirus drugs

The global outbreak of new crown pneumonia continues to worsen, with more than 10 million confirmed cases, and the entire scientific community is eagerly searching for effective antiviral therapies. Kinase is a potential target for new coronavirus drugs, and some drugs targeting kinase activity can inhibit viral infections, an international team of researchers has found in a recent study published in the journal Cell. The researchers say they have identified several kinase drugs that have antiviral effects and hope to be clinically tested as soon as possible.

In the study, a team of researchers from the United States, Britain, Germany, France and other countries used mass spectrometry to analyze how the new coronavirus modifies its host protein to facilitate the spread of the virus. They found that the new coronavirus infection changes the activity of protein kinases, which in turn changes the pattern of protein phosphorylation. The researchers believe the findings suggest that kinase is a potential target for suppressing the virus and treating new coronary pneumonia.

Through the analysis of phosphorylation site mapping, the researchers confirmed the altered kinases and signal transduction paths of the new coronavirus infection, and found that inhibiting the five kinases, p38, CK2, CDKs, AXL, and PIKFYVE, would act as antivirals. They then tested 68 drugs and compounds and found that a variety of drugs, including Gilteritinib and Apilimod, had antiviral effects, either approved for clinical use, were in clinical trials or were still in pre-clinical development. Researchers believe that cocktail therapy using these drugs may be effective in treating new coronavirus infections, similar to the use of antiretroviral therapy for AIDS.

The researchers point out that kinases have structural characteristics and potential to be targeted for new coronavirus drugs, and that since drugs for kinase are available, they should be clinically tested as soon as possible.